FSSAI Bans Non-Compliant ORS Drinks — Court Stay on ₹180 Crore Stock Raises Eyebrows

Key Takeaways

• FSSAI bans non-compliant “ORS” drinks for misleading consumers.
• Some beverages contained excessive sugar and failed WHO-approved formulations.
• Delhi High Court allows one company to sell existing ₹180 crore stock.
• Doctors call it a partial victory — warning that consumer safety must come first.

Why Did FSSAI Ban These Drinks?

The FSSAI took action after discovering that several beverages were using the term “ORS” — short for Oral Rehydration Salts — without actually meeting the medical formula set by the World Health Organization (WHO).

Many of these drinks had high sugar content and imbalanced electrolytes, making them unsafe for treating dehydration or diarrhoea, especially in children.

Doctors had been raising this issue for years, claiming that these so-called “hydration drinks” were misleading families into thinking they were safe substitutes for real ORS.

After an 8-year campaign by paediatricians like Dr. Sivaranjani Santosh from Hyderabad, FSSAI finally banned the misleading labels, saying that only WHO-compliant formulations can use the word “ORS.”

The ORSL Controversy and the Court’s Role

One major company, JNTL Consumer Health (India) — the maker of the “ORSL” drink — was directly affected by this order.

The company approached the Delhi High Court, arguing that it had followed older permissions from FSSAI which allowed it to use “ORS” in the brand name with a disclaimer.

The court granted a *temporary stay, allowing the company to *sell off ₹180 crore worth of existing stock, which is currently sitting in warehouses and stores across India.

While this provides short-term relief for the company, many health experts say it could confuse consumers who still see the misleading “ORS” branding on bottles.

Is It Fair to Sell the ₹180 Crore Stock?

This question has divided opinion.

From a business point of view:

• The company says it invested heavily based on earlier permissions.
• A sudden ban would cause heavy financial losses and job impact.

From a public health point of view:

• Experts argue that selling these drinks, even temporarily, risks public confusion.
• Parents may still buy these thinking they’re genuine medical ORS.
• Doctors say this weakens the very purpose of the ban — protecting people’s health.

So, while legally the court’s stay seems fair to the manufacturer, ethically, it’s being called “a setback for consumer safety.”

📊 Real Facts and Figures

The Good and the Bad

✅ What’s Good

• Consumer protection strengthened — only real ORS will remain in the market.
• Transparency — buyers can trust that “ORS” means the medically correct solution.
• Health awareness — the issue has started a nationwide conversation about misleading drinks.

⚠ What’s Bad

• Financial hit for beverage companies.
• Market confusion — during transition, old and new labels may mix.
• Partial enforcement — the stay order delays full consumer protection.

Expert Reactions

Health professionals have largely welcomed FSSAI’s action.
Dr. Santosh, whose 8-year battle triggered the ban, said:

“This is a win for consumers and children. Drinks high in sugar are not medicine. They must not hide behind the name ‘ORS’.”

However, legal experts note that FSSAI may need to issue clear transition guidelines for companies, so that genuine businesses can adjust without chaos.

Conclusion

The FSSAI’s decision is a strong step toward cleaner, safer labelling in India’s health-drink market.
But the court stay on existing stock shows how difficult it is to balance public health and business rights.

For now, consumers should stay alert:
Only buy WHO-approved ORS sachets or bottles from trusted pharmacies — not from supermarket shelves claiming “ORS-like” benefits.

Until the legal dust settles, India’s hydration shelves will continue to stir debate — between profits, packaging, and public health.